908 Devices Posts 21% Q4 Revenue Growth and Positive EBITDA
908 Devices shipped 224 handheld analyzers in Q4, lifting its installed base to 3,736 units and raising continuing-operations revenue 21% year over year to $17.4 million, while driving adjusted EBITDA to a positive $0.7 million from a prior $4.0 million loss. Full-year 2025 revenue rose 18% to $56.2 million with recurring revenue at 35% of sales, ending the year with $113 million in cash and no debt, and management forecasts 2026 revenue growth of 15–20% to $64.5–67.5 million.
1. Q4 Financial Performance
908 Devices shipped 224 handheld analyzers in the fourth quarter, raising continuing-operations revenue to $17.4 million, up 21% year over year. Gross margin climbed to 53% (57% adjusted), adjusted EBITDA turned positive at $0.7 million versus a prior $4.0 million loss, and net income reached $4.4 million.
2. Full-Year 2025 Results
Full-year revenue reached $56.2 million, up 18% from 2024, with recurring revenue comprising 35% of total sales and state and local channel revenue rising 38% to $24 million. Adjusted EBITDA loss narrowed 39% to $9.6 million, net loss from continuing operations improved to $33.3 million, and year-end cash stood at $113 million with no debt.
3. Operational Highlights and Product Developments
The company consolidated U.S. federal contracting to a single partner, Mountain Horse Solutions, to streamline procurement. International sales accounted for 27% of revenue, aided by increased NATO defense budgets. Key product milestones included the July 2025 VipIR launch, MX908 enhancements, and a next-generation mass spectrometry platform on track for late-2026.
4. 2026 Outlook
Management projects 2026 revenue of $64.5 million to $67.5 million, representing 15–20% growth year over year, with targeted margin expansion and a plan to halve the 2025 adjusted EBITDA loss to mid-single-digit millions.